Influence of donepezil to behavioral and psychological symptoms of frontotemporal dementia

Influence of donepezil to behavioral and psychological symptoms of frontotemporal dementia - Donepezil in frontotemporal dementia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003239

Enrollment

Registered

2010-02-23

Start date

2008-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frontotemporal dementia

Interventions

Discontinuation of donepezil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Mini-Mental State Examination(MMSE)score ranges between 5 and 26. 2.Age ranges between 50 and 90 years old. 3.Outpatients 4.Subjects are misdiagnosed AD at other clinics, prescribed denepezil, and then diagnosed FTD at our outpatient clinic. FTD is diagnosed according to the clinical diagnostic criteria for FTD in frontotemporal lobar degeneration (Neary D et al. Neurology 1998; 51: 1546-1554). 5.Findings of cranial MRI or CT examined within 1 year before entory agree with diagnosis of FTD. 6.Written informed consent is obtained from subjects or their relatives before entry.

Exclusion criteria

Exclusion criteria: 1.delirium due to metabolic intoxication and drug use 2.alcoholism, stroke, depression, manic state, and schizophrenia before the onset of FTD 3.previous use of tranquilizers and antidepressants 4.neoplastic disease and acute inflammation.

Design outcomes

Primary

Measure	Time frame
Neuropsychiatric Inventory	—

Secondary

Measure	Time frame
Zarit Burden Interview	—

Countries

Japan

Contacts

Public ContactTakemi Kimura

National Hospital Organization Kikuchi Hospital Division of Clinical Research

tkimura@kikuti.hosp.go.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026